- Medical College of Georgia research shows beneficial effects from use of CBD oil to treat COVID-19 symptoms
- CBD oil found to increase apelin levels in the human body, a key peptide needed to reduce lung inflammation resulting from COVID-19
- PacRoots Cannabis specializes in developing premium quality strains, including plants with high CBD content, rare terpene contents, which could potentially be used for medicinal purposes
Pac Roots Cannabis (CSE: PACR) (OTCQB: PACRF) has developed a strong reputation within the global cannabis sector for producing premium quality strains and products through the employment of a meticulous, genetics-focused approach towards harvesting its crops. Following a remarkable study into the potential beneficial effects of CBD oil, the Canada-based cannabis manufacturer may potentially find itself at the forefront in the development of a remedial drug in the battle against COVID-19 (https://cnw.fm/4nngU).
Cytokine, a type of protein secreted by immune cells in response to inflammation and infection, has been found to regulate the maturation, growth, and responsiveness of particular cell populations – thereby playing an important role in the human body’s immune systems. However, an overactive cytokine response resulting from a potentially acute case of COVID-19 could also result in severe patient lung damage and, in certain cases, even lead to death.
Researchers have found that a naturally occurring peptide called Apeline, which is traditionally produced in the heart, lungs, brain and blood and works as a key regulator in helping to normalize blood pressure and inflammation within the human body, may act as a suitable foil to cytokine.
A recently published study carried out by scientists at the Medical College of Georgia and Dental College of Georgia (https://cnw.fm/C5hx0) found that CBD oil was shown to habitually increase apelin levels, in addition to improving blood oxygen content and reducing inflammation – and thus, the lung damage incurred through cytokine activity.
In the study, scientists investigated a disease called adult respiratory distress syndrome (“ARDS”), the effects of which can result in similar lung tissue damage to that seen in severe COVID-19 cases. In the studies, blood levels of apelin were found to drop to almost zero in the midst of the disease but increased nearly twenty-fold when CBD was administered.
“CBD almost brought it back to a normal level,” stated Dr Jack Yu from the Medical College of Georgia when elaborating on the effects of CBD usage on apelin levels present in the human bloodstream.
While researchers were cautious on the study’s results given the need for further in-depth research into the field, it was evident that there was a strong existing correlation between ARDS and the role of apelin in reversing lung tissue damage, as well as the benefits of increasing apelin levels through CBS treatment (https://cnw.fm/tkedQ).
Pac Roots Cannabis has been a pioneer within the cannabis sector in terms of improving and modifying the genetic make-up of their cannabis product, most recently through a strategic licensing agreement with Phenome Once Corp. The agreement granted Pac Roots access to one of Canada’s largest live genetic cannabis libraries with lab and field-tested, selectively bred seedlings. The Company has employed these to grow, breed and clone its own unique brands.
The tie-up has enabled Pac Roots to offer its customers a remarkable portfolio of over 350 meticulously designed cultivars, including CBD-dominant plants possessing rare terpene profiles. Due to its specialty CBD plant offerings, Pac Roots appears well positioned to benefit from CBD’s positive effects on assuaging COVID-19 complications.
For more information, visit the company’s website at www.PacRoots.ca.
NOTE TO INVESTORS: The latest news and updates relating to PACR are available in the company’s newsroom at http://cnw.fm/PACR
About CBDWire
CBDWire (CBDW) is a specialized information provider focused on (1) reporting CBD-related news and updates, (2) releasing CBDNewsBreaks crafted to keep investors abreast of the latest and greatest in the CBD market, (3) refining and enhancing corporate press releases, (4) delivering end-to-end distribution and social media services to client-partners and (5) constructing effective corporate communication solutions based on the unique requirements of CBD companies. CBDW is exclusively positioned in the burgeoning CBD sector with a proven team of journalists and researchers working to deliver high quality content to an expansive target audience of investors, consumers and industry news outlets. Our dissemination network of over 5,000 downstream distribution points allows us to deliver unparalleled reach, visibility and recognition to companies operating in both cannabidiol and the wider cannabis space. CBDWire (CBDW) is where CBD news, content and information converge.
To receive instant SMS alerts, text CBDWire to 21000 (U.S. Mobile Phones Only)
For more information please visit https://www.CBDWire.com
Please see full terms of use and disclaimers on the CBDWire website applicable to all content provided by CBDW, wherever published or re-published: https://CBDWire.com/Disclaimer
Do you have questions or are you interested in working with CNW? Ask Our Editor
CBDWire (CBDW)
Denver, Colorado
www.CBDWire.com
303.498.7722 Office
Editor@CBDWire.com
CBDWire is part of the InvestorBrandNetwork.